After-hours movers: UiPath, SentinelOne, Under Armour, and more

Altria (MO) PT Raised to $47 at Goldman Sachs

Goldman Sachs analyst Bonnie Herzog raised the price target on Altria (NYSE: MO) to $47.00 (from $46.00) while maintaining a Buy rating.

The analyst comments "Our View - We adjust our EPS estimates following the pricing today of MO's offering of ABI stock at $62.50 per... More

UiPath Inc. (PATH) PT Raised to $29 at Macquarie, 'Clearing a PATH for 2025 growth'

Macquarie analyst Frederick Havemeyer raised the price target on UiPath Inc. (NYSE: PATH) to $29.00 (from $22.00) while maintaining a Outperform rating.

The analyst comments "PATH reported a solid FQ4, posting its first GAAP-profitable quarter and closing out FY'24 with Rule of 41 execution. Cloud ARR ~$650mn (70%+... More

Robinhood Markets (HOOD) PT Raised to $20 at Mizuho, 'Strong February Trends Solidify Our Bullish Stance'

Mizuho analyst Dan Dolev raised the price target on Robinhood Markets (NASDAQ: HOOD) to $20.00 (from $17.00) while maintaining a Buy rating.

The analyst comments "HOOD reported February metrics last night which shined across the board. The stock is reacting positively today. AUC accelerated to... More

Buy Robinhood (HOOD) stock to play 'a monster of a crypto cycle' - Bernstein

The crypto market rally is continuing, and analysts at financial research firm Bernstein believe Robinhood (NASDAQ: HOOD) is a stock to consider to play "a monster of a crypto cycle over 2024-25."

Robinhood's stock jumped Thursday after reporting its February operating date, which saw funded customers at the end of the month rise approximately 130 thousand from January 2024.

Meanwhile, assets under custody (AUC) at the end of February were $118.7 billion, up 16% from January 2024. Net deposits were $3.6 billion in February, translating to a 42% annualized growth... More

Altria Group (MO) Halted, News Pending

Altria Group (NYSE: MO) Halted, News Pending

Spruce Biosciences, Inc. (SPRB) PT Lowered to $4 at Oppenheimer

Oppenheimer analyst Hartaj Singh lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $4.00 (from $7.00) while maintaining a Outperform rating.

The analyst comments "Spruce (SPRB) announced top-line results from the CAHmelia-203 and CAHptain-205 studies of tildacerfont in adult and pediatric classic CAH,... More

Turtle Beach Corporation (HEAR) PT Raised to $25 at Roth/MKM

Roth/MKM analyst Sean McGowan raised the price target on Turtle Beach Corporation (NASDAQ: HEAR) to $25.00 (from $17.00) while maintaining a Buy rating.

The analyst comments "Our thesis on HEAR has been that the share price would be driven higher by either... More

SentinelOne Inc (S) PT Raised to $30 at Loop Capital

Loop Capital analyst Yun Kim raised the price target on SentinelOne Inc (NYSE: S) to $30.00 (from $28.00) while maintaining a Buy rating.

The analyst comments "SentinelOne reported a steady F4Q, representing its third consecutive quarter of at least in-line quarter. It also provided in-line F1Q and FY25 top-line guidance. Overall, its results over the last three quarters indicate that its business trends continue to stabilize and that its sales execution has largely adjusted to the current sales environment which remains challenging. Its NRR also stabilized at 115%+ for the past three quarters. However, with... More

Turtle Beach Corporation (HEAR) PT Raised to $17 at Stifel

Stifel analyst Drew Crum raised the price target on Turtle Beach Corporation (NASDAQ: HEAR) to $17.00 (from $14.00) while maintaining a Buy rating.

The analyst comments "On Wednesday after the market close, Turtle Beach made several announcements, notably the acquisition of Performance Design Products,... More

UiPath Inc. (PATH) PT Raised to $30 at Needham

Needham analyst Scott Berg raised the price target on UiPath Inc. (NYSE: PATH) to $30.00 (from $25.00) while maintaining a Buy rating.

The analyst comments "UiPath reported impressive 4Q results with top and bottom line beats driven by accelerating deal flow and strong platform sales. The... More

UiPath Inc. (PATH) PT Raised to $28 at TD Cowen

TD Cowen analyst Bryan Bergin raised the price target on UiPath Inc. (NYSE: PATH) to $28.00 (from $25.00) while maintaining a Outperform rating.

The analyst comments "PATH posted a strong close to FY24 w/ beats across the board (incl robust op inc & FCF)... More

Evercore ISI Downgrades Under Armour, Inc. (UAA) to Underperform, 'Founder's Return Suggests Turn Isn't Progressing'

Evercore ISI analyst Michael Binetti downgraded Under Armour, Inc. (NYSE: UAA) from In Line to Underperform with a price target of $7.00 (from $8.00).

The analyst comments "Downgrade UAA to Underperform from In Line: Last night, UAA announced that founder Kevin Plank will return as... More

JPMorgan Upgrades UiPath Inc. (PATH) to Overweight, 'Tailwind from AI Projects Takes Shape'

JPMorgan analyst Mark Murphy upgraded UiPath Inc. (NYSE: PATH) from Neutral to Overweight with a price target of $28.00 (from $22.00).

The analyst comments "We are upgrading UiPath shares to OW from Neutral as we anticipate the period of ARR growth decel transitioning into a... More

Robinhood Markets (HOOD) PT Raised to $16 at Deutsche Bank, 'Positive transaction revenue outlook from February metrics'

Deutsche Bank analyst Brian Bedell raised the price target on Robinhood Markets (NASDAQ: HOOD) to $16.00 (from $12.00) while maintaining a Hold rating.

The analyst comments "Positive transaction revenue outlook from February metrics. We view HOOD's February metrics report as being relatively good overall. Most positively, notional trading volumes were up across all asset classes vs. January levels and trending better than our 1Q estimates (before the metrics print) for equities and options, driven by especially strong equities notional volume of... More

UiPath Inc. (PATH) PT Raised to $30 at BofA Securities

BofA Securities analyst Brad Sills raised the price target on UiPath Inc. (NYSE: PATH) to $30.00 (from $26.00) while maintaining a Buy rating.

The analyst comments "UiPath reported strong Q4 results, with revenue and ARR (annual recurring revenue) both exceeding our estimates. ARR of $1.464... More

UiPath Inc. (PATH) PT Raised to $25 at Morgan Stanley

Morgan Stanley analyst Keith Weiss raised the price target on UiPath Inc. (NYSE: PATH) to $25.00 (from $17.00) while maintaining a Equalweight rating.

The analyst comments "UiPath reported a strong 6% revenue beat on license outperformance with +22% YoY ARR growth coming ahead of expectations, which... More

SentinelOne Inc (S) PT Raised to $24 at DA Davidson, 'not quite enough to get us off the sidelines'

DA Davidson analyst Rudy Kessinger raised the price target on SentinelOne Inc (NYSE: S) to $24.00 (from $22.00) while maintaining a Neutral rating.

The analyst comments "FQ4 results solidly ahead, particularly on OMs, although the ARR beat was very modest relative what CRWD (BUY)... More

UiPath Inc. (PATH) PT Raised to $24 at DA Davidson, 'Platform approach continuing to bear fruit'

DA Davidson analyst Gil Luria raised the price target on UiPath Inc. (NYSE: PATH) to $24.00 (from $20.00) while maintaining a Neutral rating.

THe analyst comments "PATH's F4Q24 demonstrated continued momentum in penetrating the existing base of enterprise customers with long runways to adopt a platform approach to... More

UiPath Inc. (PATH) PT Raised to $27 at Evercore ISI, 'Profitable Path Forward'

Evercore ISI analyst Kirk Materne raised the price target on UiPath Inc. (NYSE: PATH) to $27.00 (from $24.00) while maintaining a In Line rating.

The analyst comments "UiPath delivered a solid finish to FY24 with revenue, ARR, and operating profit all coming in nicely ahead of expectations. In addition, the initial FY25 ARR guide of $1,727.5mn (+18%) is slightly ahead of the Street at $1,699.2mn (+17%) and infers that... More